Opus Genetics Inc. announced positive three-month data from the pediatric cohort of its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, an investigational gene augmentation therapy for Leber congenital amaurosis type 5 (LCA5). According to the company, all three pediatric participants demonstrated improvements in cone-mediated vision, and the therapy was well tolerated without any ocular serious adverse events or dose-limiting toxicities. Durable responses were also observed in adult participants out to 18 months. The results were discussed during a company webcast and conference call. Opus Genetics expects to meet with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to discuss these findings and the next steps for the OPGx-LCA5 program.